Expansion of the genotypic and phenotypic spectrum of CTCF‐related disorder guides clinical management: 43 new subjects and a comprehensive literature review

• Published in: American journal of medical genetics. Part A Vol. 191; no. 3; pp. 718 - 729
• Main Authors: Valverde de Morales, Hannah Gabriela, Wang, Hsiao‐Lin V., Garber, Kathryn, Cheng, Xiaodong, Corces, Victor G., Li, Hong
• Format: Journal Article
• Language: English
• Published: Hoboken, USA John Wiley & Sons, Inc 01.03.2023; Wiley Subscription Services, Inc
• Subjects: Congenital defects; Craniofacial growth; CTCF; facial gestalt; gene; Genetic counseling; Genotype; Hereditary diseases; Humans; Intellectual disabilities; Intellectual Disability - diagnosis; Intellectual Disability - genetics; Language Development Disorders - genetics; Literature reviews; Mutation; Neurodevelopmental disorders; Phenotype; variant; phenotype; variant; CTCF; facial gestalt; gene; genotype
• DOI: 10.1002/ajmg.a.63065
• ISSN: 1552-4825; 1552-4833

Monoallelic variants of CTCF cause an autosomal dominant neurodevelopmental disorder with a wide range of features, including impacts on the brain, growth, and craniofacial development. A growing number of subjects with CTCF‐related disorder (CRD) have been identified due to the increased application of exome sequencing, and further delineation of the clinical spectrum of CRD is needed. Here, we examined the clinical features, including facial profiles, and genotypic spectrum of 107 subjects with identified CTCF variants, including 43 new and 64 previously described subjects. Among the 43 new subjects, 23 novel variants were reported. The cardinal clinical features in subjects with CRD included intellectual disability/developmental delay (91%) with speech delay (65%), motor delay (53%), feeding difficulties/failure to thrive (66%), ocular abnormalities (56%), musculoskeletal anomalies (53%), and behavioral problems (52%). Other congenital anomalies were also reported, but none of them were common. Our findings expanded the genotypic and phenotypic spectrum of CRD that will guide genetic counseling, management, and surveillance care for patients with CRD. Additionally, a newly built facial gestalt on the Face2Gene tool will facilitate prompt recognition of CRD by physicians and shorten a patient's diagnostic odyssey.